Prescription drugs can deliver high doses of phthalates

http://www.environmentalhealthnews.org/ehs/news/prescription-drugs-can-deliver-high-doses-of-phthalates

For millions of people, medicines are a 
little-known, major source of the compounds, 
which are linked to reproductive abnormalities. 
Scientists warn “of the potential for high 
delivered doses of phthalates to vulnerable 
segments of the population, particularly pregnant women or young children.”

  By Marla Cone
  Editor in Chief
  Environmental Health News
  published 10 November 2008

    Every day for three months, the patient took 
a prescription drug called Asacol to treat his inflamed colon.

    Unbeknownst to him, every pill he swallowed 
also delivered a dose of a hormone-altering, industrial chemical.

     The man, who lived in the Boston area, was 
contaminated with about 100 times more dibutyl 
phthalate than ever recorded before in a human 
being. His daily dose of the chemical was double 
the amount that the U.S. Environmental Protection Agency considers safe.

    At least 47 prescription 
medications--including the colitis drug Asacol, 
an antacid and an HIV drug--contain phthalates, 
according to scientists at the Harvard School of 
Public Health and U.S. Centers for Disease Control and Prevention.

    Widely used as plasticizers, phthalates have 
been linked to abnormal reproductive tracts, 
sperm damage and reduced testosterone in animal 
tests as well as some human studies.

    Russ Hauser, a Harvard professor of 
environmental epidemiology, called 
pharmaceuticals “an unrecognized source of 
potential high exposure.” A thin layer of a 
phthalate-containing polymer, designed to slow 
the release of medication, coats many timed-release drugs.

    Phthalates are found in virtually every human 
body. But for people taking medications coated 
with the compounds, their exposure exceeds other, 
well-known sources, such as plastics, perfumes 
and lotions, by ten to 1,000-fold, Hauser said.

      Phthalates are ingredients in vinyl, as 
well as some building materials, paints, 
adhesives and personal care products, including 
fragrances, shampoos and nail polishes.

    Congress enacted a law in August banning the 
chemicals in toys and other children’s products.

    But their use in prescription drugs and 
over-the-counter medications is approved by the 
U.S. Food and Drug Administration.

     New data showing high levels of phthalates 
in people taking some medications “raise concern 
about potential human health risks,” Hauser and 
his colleagues reported in a study published in 
October in Environmental Health Perspectives online.

    The scientists warned “of the potential for 
high delivered doses of phthalates to vulnerable 
segments of the population, particularly pregnant women or young children.”

      In one case, the man taking Asacol for his 
ulcerative colitis, an inflammatory bowel 
disease, had a concentration of a dibutyl 
phthalate (DBP) metabolite in his urine measuring 
nearly 17,000 parts per billion, according to a 
case study reported by the Harvard/CDC team. The 
average for the general population was 46.

    The unidentified man, in his early 30s, was 
tested for phthalates as part of a visit to a 
Boston infertility clinic. He and his wife were unable to conceive a child.

     The effects of phthalates on male fertility 
remain unknown, but some scientists theorize that 
exposure, especially in the womb, could 
contribute to an increase in men’s reproductive 
disorders, such as reduced sperm quality, 
testicular cancer and undescended testicles.

      Representatives of the plastics industry 
say the levels of phthalates used in consumer 
products are safe. They say human studies are 
small and inconclusive, and that the animals in 
studies showing effects were exposed to high doses.

    The FDA has not put restrictions on use of 
phthalates except for a 2001 guideline that 
warned hospitals that phthalate-containing 
intravenous tubing and other plastic medical 
devices exposes infants to large doses of the chemicals.

        Dr. Shanna Swan, a professor of 
obstetrics and gynecology and of environmental 
medicine at University of Rochester, called DBP, 
used in Asacol, “one of the most toxic” 
phthalates. It was associated with feminization 
of newborn boys--a shortened distance between the 
genitals and the anus­in a study that Swan and 
her colleagues published in 2005.

          About 20 million prescriptions for 
Asacol have been written in the United States 
since it was approved by the FDA in 1992, 
according to Procter & Gamble Pharmaceuticals, the drug’s manufacturer.

    “DBP is an important component of our enteric 
coating, which ensures that Asacol is delivered 
to the site of inflammation in the colon and/or 
rectum,” said Scott Docherty, external relations 
manager for Procter & Gamble Pharmaceuticals.

    Without the phthalate coating, which 
dissolves when it reaches a certain pH, the drug 
would be released in the stomach. Because DBP has 
been approved by the FDA, the company is not 
looking for alternatives, Docherty said.

     P&G’s surveillance of patients “has not 
identified any adverse events or effects” caused by the DBP, he said.

     The Boston area man was prescribed an 
extraordinary dosage of Asacol--12 pills a day, 
which is double the highest recommended dose on 
the manufacturer’s label. He took it for three 
months, twice as long as recommended.

    Docherty said for patients taking the 
recommended doses of Asacol, their DBP exposure 
is far below the EPA’s “no observed effects level.”
    “If the patient follows the labeled dose, 
even the highest dose on the label, they would be 
taking six tablets per day and there would still 
be a safety margin 100-fold below” the EPA’s guideline, Docherty said.

     But Hauser’s team recently found other 
examples of high exposure, although not as extreme as that man’s.

    The scientists analyzed a national database 
of 8,000 people, and found six, including a 
pregnant woman, who took mesalamine, the active 
ingredient in Asacol. They averaged 50 times more 
DBP metabolite in their urine than people who did 
not take the drug, and two exceeded the EPA’s 
no-effects level, the October report said.

     Another 121 people who took three other 
medications--omeprazole, used in Prilosec 
antacids; didanosine, which is sold under the 
name Videx EC and treats HIV patients; and 
theophylline, a pulmonary disease medicine­also 
had above-average levels of another phthalate, up 
to eight times higher than people who did not take the drugs.

     Swan cautioned that the Harvard/CDC study 
included small numbers of people taking the drugs 
so the averages may be distorted by a few highly 
exposed ones. Nevertheless, Swan, who did not 
participate in the study, said the data suggest 
that millions of people could be at risk.

        Baby boys exposed in the womb may be the 
most vulnerable, Hauser and Swan said.

      At least three women in the study with 
above-average phthalate levels were pregnant­one 
was taking mesalamine and two were taking the 
antacids, said Sonia Hernandez-Diaz, a Harvard 
associate professor of epidemiology who was the 
study’s lead author. Another woman of 
childbearing age who took the colitis drug had a 
daily dose of DBP exceeding the EPA’s guideline.

     “We know that high doses of DBP given to 
pregnant rats can lead to reproductive tract 
anomalies in the male offspring. Therefore, I 
would be concerned about high DBP exposure in pregnant women,” Hauser said.

     When prescribing medications to pregnant 
women, doctors should seek formulations free of the compounds, he said.

    Many people who take the medicines have a 
serious disease that may make them more 
susceptible to chemicals. HIV patients, for 
example, have a suppressed immune system.

     The authors reported that their study 
“probably underestimates the true impact of 
exposure to phthalates in medications.”

     Most notably, they did not study 
over-the-counter medications and vitamins, which 
often have timed-release coatings.

    “I think there are likely other medications 
that also contribute to very high human 
exposure,” Hauser said, adding that the number of 
problematic medications “is likely to change, up 
or down, depending on what we learn in the coming months.”


Christmas Postage from HolyPostage.com

<*}}}>< <http://www.holypostage.com/>Holy Postage <*}}}><
<*}}}><<http://www.halfthekingdom.org/>Half the Kingdom!<*}}}><


<http://holypostage.com/catalog/index.php?cPath=37>
Holy Postage Christmas

<*}}}>< <http://www.holypostage.com/>Holy Postage <*}}}><
<*}}}><<http://www.halfthekingdom.org/>Half the Kingdom!<*}}}><

--~--~---------~--~----~------------~-------~--~----~
Please note that I do not send or open attachments sent to this list. 

You received this message because you are subscribed to the Google Groups 
"Catholics on Fire" group.
To post to this group, send email to [email protected]
To unsubscribe from this group, send email to [EMAIL PROTECTED]
For more options, visit this group at 
http://groups.google.com/group/Catholics-on-Fire

May the blessing of Jesus and our Blessed Mother be with you
-~----------~----~----~----~------~----~------~--~---

Reply via email to